Skip to content
Recall Observatory FDA recall evidence

Drug product

Hydralazine HCL Tablets, USP, 25 mg in a single blister package, Manufactured in Czech Republic By: Teva Czech Industries s.r.o. Opava-Komarov, Czech Republic, Distributed by Goldline Laboratories, Sellersville, PA, NDC 00182-0554-89 (carton) and 00182-0554-00 (single blister).

D-1074-2014

December 18, 2013

Class II

Product summary

Firm
Teva Pharmaceuticals USA
Event
Event 67141
Status
Terminated
Classification
Class II
Quantity
1,249,700 tablets
Official record key
drug-enforcement:D-1074-2014

Official wording

Reason: Failed Impurities/Degradation Specifications:There is a potential for the tablets to be out of specification for impurities throughout shelf life.

Code information: lot #14071112AA; Exp. 03/14. lot #14071112AB; Exp. 03/14. lot # 14071012BA; Exp. 03/14. lot #14071012BB; Exp 03/14.

Distribution pattern: Nationwide

Derived failure modes

  • Potency or specification failure

    reason.potency_specification_failure · v1.0.0

    out of specification